Related Experiment Videos
[Lithium balance in healthy volunteers]
Pharmakopsychiatrie, Neuro-Psychopharmakologie
|September 1, 1978
Summary
This study found that a daily dose of 30 mval lithium sulfate is needed to maintain therapeutic serum levels in healthy volunteers. Renal excretion is the primary pathway for lithium elimination, with levels returning to zero within six days of discontinuation.
Area of Science:
- Pharmacokinetics
- Clinical Pharmacology
- Renal Physiology
Context:
- Lithium is a mood stabilizer used in treating bipolar disorder.
- Understanding lithium pharmacokinetics is crucial for safe and effective therapeutic use.
- Sustained-release formulations aim to improve patient compliance and reduce side effects.
Purpose:
- To evaluate the pharmacokinetic profile of lithium sulfate in a sustained-release preparation.
- To determine the daily dosage required for maintaining therapeutic lithium serum levels.
- To assess the primary route of lithium excretion and its elimination rate.
Summary:
- Three healthy volunteers received 10 days of sustained-release lithium sulfate.
- A daily dose of 30 mval achieved steady-state serum lithium concentrations (0.7–0.8 mmol/l) within 4–5 days.
- Lithium clearance averaged 26.8 ml/min, with 98% excreted renally; serum and urine lithium normalized within 6 days post-withdrawal.
Impact:
- Establishes renal excretion as the primary elimination pathway for lithium, simplifying balance studies.
- Provides data on lithium dosage requirements for maintaining therapeutic levels.
- Suggests potential interactions of lithium elimination with psychotropic drugs and sodium chloride intake.